138 related articles for article (PubMed ID: 14526272)
1. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.
Rave K; Nosek L; Heinemann L; Frick A; Becker R
Diabetes Metab; 2003 Sep; 29(4 Pt 1):430-1. PubMed ID: 14526272
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
4. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988-1995.
DeVries JH
Diabetologia; 2006 May; 49(5):1125-6. PubMed ID: 16520920
[No Abstract] [Full Text] [Related]
5. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection.
Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT
Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727
[No Abstract] [Full Text] [Related]
6. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
8. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
[TBL] [Abstract][Full Text] [Related]
9. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
Albright ES; Desmond R; Bell DS
Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
12. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
13. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
14. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
15. Theoretical pharmacokinetic advantages and methodological flaws: glargine is not superior to NPH insulin in children with type 1 diabetes mellitus.
Dora JM; Scheffel RS
Arq Bras Endocrinol Metabol; 2010 Feb; 54(1):81-3. PubMed ID: 20414553
[No Abstract] [Full Text] [Related]
16. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R
Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
Pan CY; Sinnassamy P; Chung KD; Kim KW;
Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
[TBL] [Abstract][Full Text] [Related]
19. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
[TBL] [Abstract][Full Text] [Related]
20. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.
Forst T; Larbig M; Hohberg C; Forst S; Diessel S; Borchert M; Roth W; Pfützner A
Diabetes Obes Metab; 2010 May; 12(5):437-41. PubMed ID: 20415692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
